Ministry of Health purchases high-priced oncology drugs | Video Minsa Cancer UNEP Cesar Vásquez Latest News | Lime

he ministry of health (Minsa) purchases high-cost oncology medicines not included in the Single National Medicines Requirement (PNUME) and closes the gap in access to new treatments for cancer patients.

The acquisition is designed to enhance cancer patients’ access to new and better oncology treatments.

More information | SJL: Blackmailer shoots at kindergarten because owner failed to pay fees

Sanitation Committee, Cesar VazquezHe has made the fight against cancer a priority since taking office, and since then he has been taking important steps to improve access to new oncology treatments.

According to him Minsathis disease is a public health problem at the national level that requires multiple simultaneous interventions, especially the promotion of healthy lifestyles and vaccination against hepatitis B and human papillomavirus.

At the same time, we will strengthen early cancer screening and diagnosis, promptly deal with precancerous lesions, and diagnose, stage and treat cancer.

director Minsa Cancer Prevention and ControlVíctor Palacios reports that there has been a gap in access to new treatments in oncology services for 15 years.

“Thanks to the MEF’s budget allocation, the process of closing the gap in access to new oncology treatments begins, implementing the provisions of the regulated National Cancer Act that puts patients first and puts them at the forefront of all our efforts. center”he pointed out.

“Getting medicines to people with cancer is a public health priority and our goal is that people with cancer have immediate access to the treatment they need.”Palacios added.

and obtain and use PertuzumabThe Minsa Agency for Cancer Prevention and Control purchases other drugs for SIS cancer patients through Cenares, such as: Pembrolizumab (immunotherapy), pemetrexed and fulvestrant.

In addition, pegylated asparaginase, idarubicin, nilotinib, sorafenib, clofarabine, lapatinib, liposomal doxorubicin, nivolumab, lenatinib Rapid acquisition and distribution are expected to be achieved with duramide, denosumab, plerixafor, osimertinib, alectinib, methalan, subcutaneous rituximab, arsenic trioxide, and olaparib.

Check here | Man attacked with knife inside a restaurant in San Juan de Lurigancho